Registration number: 04088271

Medisave (UK) Limited

Contents

Medisave (UK) Limited

Company Information

Medisave (UK) Limited

Strategic Report for the Year Ended 31 December 2024

The directors present their strategic report for the year ended 31 December 2024.

Principal activity

The principal activity of the company is the sale of medical products.

Fair review of the business, development and performance

Medisave (UK) Limited derives income from the sale of Covid related medical equipment and PPE to the UK and non-uk markets.Non UK market sales make up less than 0.058% (PY less than 0.00052%) of the total. There is also the company's share of profit from the Medisave UK partnership. In addition the company holds the Pharmaceutical Licence that the partnership requires to sell pharmaceutical products. A licence fee is paid by the partnership to the company. There is also a small amount received from renting to the partnership the plant and equipment owned by the company.

The year's results for the company, set out on page 9, show a profit before tax of £445,698 compared with a profit before tax of £1,338,447 for the previous year ended 31 December 2023.

The company's key financial and other performance indicators during the year were as follows:

Principal risks and uncertainties

The company's principal financial instruments comprise cash at bank, stock, receivables and payables and the main purpose of these instruments is to finance the company's operations. The policy of the company is to ensure that credit risk and cash flow risks are minimised. Credit and cash flow risk is mitigated by proactive credit management policies of all receivables. Liquidity risk in respect of payables is managed by ensuring sufficient funds are available to meet amounts due. As a result of these objectives and policies, the directors' consider that the company's overall exposure to financial risk is low.

Approved and authorised by the Board on 23 December 2025 and signed on its behalf by:
 

Medisave (UK) Limited

Directors' Report for the Year Ended 31 December 2024

The directors present their report and the financial statements for the year ended 31 December 2024.

Directors of the company

The directors who held office during the year were as follows:

Mrs Melissa Helen Denton-Benson

Mr Graham Andrew Wright - Company secretary and director

Mr Matthew James Denton

Mrs Nicola Jane Wright

Mr Nathan Castle

Mrs Emily Bush

Mr Ashley Newman (appointed 1 December 2024)

Disclosure of information to the auditors

Reappointment of auditors

In accordance with section 485 of the Companies Act 2006, a resolution for the re-appointment of Scott Vevers Ltd as auditors of the company is to be proposed at a General Meeting.

Approved and authorised by the Board on 23 December 2025 and signed on its behalf by:
 

Medisave (UK) Limited

Statement of Directors' Responsibilities

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Medisave (UK) Limited

Independent Auditor's Report to the Members of Medisave (UK) Limited

Opinion

We have audited the financial statements of Medisave (UK) Limited (the 'company') for the year ended 31 December 2024, which comprise the Profit and Loss Account, Statement of Comprehensive Income, Balance Sheet, Statement of Changes in Equity, Statement of Cash Flows, and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
 

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Medisave (UK) Limited

Independent Auditor's Report to the Members of Medisave (UK) Limited

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Directors' Report.

Medisave (UK) Limited

Independent Auditor's Report to the Members of Medisave (UK) Limited

Auditor Responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities, and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with directors and other management, and from our commercial knowledge and experience of the company sector;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, taxation legislation and data protection, employment and health and safety legislation;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.
We assessed the susceptibility of the company’s financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:
- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected, and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:
- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.
In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims.

 

Medisave (UK) Limited

Independent Auditor's Report to the Members of Medisave (UK) Limited

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission, or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.
 

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

......................................
Marcus Cridland BA (Hons) FCA (Senior Statutory Auditor)
For and on behalf of Scott Vevers Ltd, Statutory Auditor

65 East Street
Bridport
Dorset
DT6 3LB

23 December 2025

Medisave (UK) Limited

Profit and Loss Account for the Year Ended 31 December 2024

The above results were derived from continuing operations.

The company has no recognised gains or losses for the year other than the results above.

Medisave (UK) Limited

Statement of Comprehensive Income for the Year Ended 31 December 2024

Medisave (UK) Limited

(Registration number: 04088271)
Balance Sheet as at 31 December 2024

Approved and authorised by the Board on 23 December 2025 and signed on its behalf by:
 

Medisave (UK) Limited

Statement of Changes in Equity for the Year Ended 31 December 2024

Medisave (UK) Limited

Statement of Cash Flows for the Year Ended 31 December 2024

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Medisave House,
Mercery Rd,
Weymouth
Dorset
DT3 5FA

The principal place of business is:
Medisave House,
Mercery Rd,
Weymouth
Dorset
DT3 5FA

These financial statements were authorised for issue by the Board on 23 December 2025.

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

Basis of preparation

Revenue recognition

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

Tangible assets

Depreciation

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is earned at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

Business combinations

Investments

Cash and cash equivalents

Trade debtors

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Stocks

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash end bank balances, ore initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment

Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in profit or loss

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.




Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Other financial liabilities
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair valueon the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities
Financial liabilities are derecognised when the company's contractual obligations expire or are discharged or cancelled.

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash end bank balances, ore initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment

Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in profit or loss

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.




Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Other financial liabilities
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair valueon the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities
Financial liabilities are derecognised when the company's contractual obligations expire or are discharged or cancelled.

Trade creditors

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Borrowings

Leases

Share capital

Defined contribution pension obligation

Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

Judgements and key sources of estimation uncertainty
In the application of the company's accounting policies, the directors' are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

The analysis of the company's revenue for the year from continuing operations is as follows:

Arrived at after charging/(crediting)

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

The aggregate payroll costs (including directors' remuneration) were as follows:

The average number of persons employed by the company (including directors) during the year, analysed by category was as follows:

There were no directors to whom retirement benefits under money purchase schemes were accruing.

The directors' remuneration for the year was as follows:

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Tax charged/(credited) in the income statement

	Plant and equipment £	Total £
Cost or valuation
At 1 January 2024	129,188	129,188
At 31 December 2024	129,188	129,188
Depreciation
At 1 January 2024	52,638	52,638
Charge for the year	11,483	11,483
At 31 December 2024	64,121	64,121
Carrying amount
At 31 December 2024	65,067	65,067
At 31 December 2023	76,550	76,550

12	Investments

	2024  £	2023  £
Investment in subsidiary - 1000 1 euro shares in Medisave EU Holding B.V. a company incorporated in the Netherlands registered number 91692822	835	-

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

	Investment in the Medisave UK Partnership £	Total £
Cost or valuation
At 1 January 2024	12,976,047	12,976,047
Movement in year	497,125	497,125
At 31 December 2024	13,473,172	13,473,172

As well as its own trading activities, the company is a partner in the Medisave UK Partnership. The investment represents the company's current and capital accounts as shown in the Partnership accounts. As a partner the company provides security for partnership loans which appear in these accounts. Details of the security given are shown in Note 20 of these accounts. The partnership's principal place of business is Medisave House, Mercery Road, Weymouth DT3 5FA.

 

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Allotted, called up and fully paid shares

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Charges given in support of bank borrowings

Operating leases

The total of future minimum lease payments is as follows:

The amount of non-cancellable operating lease payments recognised as an expense during the year was £15,006 (2023 - £23,301).

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Summary of transactions with entities with joint control or significant interest
Medisave US LLP - an entity under common control. Medisave (UK) supplies goods as well as a line of credit in the form of paying for transactions relating to Medisave US LLP. In 2024 the supply of goods totalled £454 (PY 2023 £4,151). The outstanding amount owed by Medisave US LLP at 31 December 2024 in respect of goods was £2 (PY 2023 £7,693). The transactions paid for on behalf of Medisave US LLP in 2024 totalled £78,414 (PY 2023 £53,314). The amount outstanding in respect of transactions paid at 31 December 2024 was £93,774 (PY £53,314)

Stethoscope Canada - an entity under common control. Medisave (UK) supplies goods as well as a line of credit in the form of paying for transactions relating to Stethoscope Canada. In 2024 the supply of goods totalled £0 (PY 2023 £15,018). The amount owed by Stethoscope Canada at 31 December 2024 in respect of goods was £14,280 (PY 2023 £15,018). The transactions paid for on behalf of Stethoscope Canada in 2024 totalled £5,128 (PY 2023 £2,733) . The amount outstanding in respect of transactions paid at 31 December 2024 was £7,727 (PY £2,733).

Medisave Australasia - an entity under significant influence. Medisave (UK) supplies goods as well as a line of credit in the form of paying for transactions relating to Medisave Australasia. In 2024 the supply of goods totalled £7,470 (PY 2023 £7,758). The outstanding amount owed by Medisave Australasia at 31 December 2024 in respect of goods was £44,855 (PY 2023 £44,991). The transactions paid for on behalf of Medisave Australasia in 2024 totalled £724 (PY 2023 £2,636) The amount outstanding in respect of transactions at 31 December 2024 was £3,542 (PY 2023 £2,964)

POD Technical Ltd - an entity under common control. Medisave (UK) Ltd supplies and purchases goods. In 2024 the supply of goods totalled £100 (PY 2023 £Nil) .The outstanding amount owed by POD Technical Ltd at 31 December 2024 in respect of goods supplies was £100 (PY2023 £Nil). In 2024 the purchase of goods from POD Technical Ltd totalled £50,343 (PY 2023 £25,927). The outstanding amount owed to POD Technical Ltd at 31 December 2024 was £2,032 (PY 2023 owing by £1,070)

Wessex Equity Partnership - an entity under significant influence. Medisave (UK) Ltd purchases services and for 2024 totalled £119,781 (PY 2023 £127819). The outstanding amount owed to Wessex Equity Partnership at 31 December 2024 was £18,628 (PY 2023 £34,666)

Medscope Medical Supplies Ltd - an entity under common control. Medisave (UK) supplies and purchases goods as well as a line of credit in the form of paying for transactions relating to Medscope Medical Supplies Ltd. In 2024 the supply of goods totalled £312 (PY 2023 £323,669).The outstanding amount owed by Medscope Medical Supplies Ltd as at 31 December 2024 in respect of goods supplies was £Nil (PY2023 £4,898). In 2024 the purchase of goods from Medscope Medical Supplies Ltd was £14,980 (PY 2023 £1,014l) The outstanding amount owed to Medscope Medical Supplies Limited at 31 December 2024 was £13,083 (PY 2023 £1,014l). The transactions paid for on behalf of Medscope Medical Supplies Ltd in 2024 totalled £20,398 (PY 2023 £54,672) The net position at 31 December 2024was that monies were due to Medscope Medical Supplies Ltd of £20,840 (PY 2023 £30,462)

Medisave (UK) Limited

Notes to the Financial Statements for the Year Ended 31 December 2024

Medipro Medical Products Limited - an entity under common control. Medisave (UK) supplies goods as well as a line of credit in the form of paying for transactions relating to Medipro Medical Products Limited. In 2024 the supply of goods totalled £37,166 (PY 2023 £45,722). The outstanding amount owed by Medipro Medical Products Limited at 31 December 2024 in respect of goods was £10,866 (PY 2023 £Nil ). The transactions paid for on behalf of Medipro Medical Products Limited in 2024 totalled £94 (PY 2023 £4,716) The amount outstanding owed to Medipro Medical Products Limited at 31 December 2024 was £153,805.

Wykeside Technologies Limited - an entity under significant influence - provides services and for 2024 totalled £8,071 (PY 2023 £10,224). The amount owed to Wykeside Technologies Limited at 31 December 2024 was £Nil (PY 2023 £Nil)

Medisave EU Germany - an entity under common control. Medisave (UK) supplies goods as well as a line of credit in the form of paying for transactions relating to Medisave EU Germany. In 2024 the supply of goods totalled £6,382 (PY 2023 £Nil). The outstanding amount owed by Medisave EU Germany at 31 December 2024 in respect of goods was £11,716 (PY 2023 £Nil ). The transactions paid for on behalf of Medisave EU Germany in 2024 totalled £3,572 (PY 2023 £4,486) The amount outstanding owed by Medisave EU Germany at 31 December 2024 was £13,814 (PY 2023 £10,771)

Medisave BV Netherlands - an entity under common control. Medisave (UK) supplies goods and in 2024 the supply of goods totalled £33,703 (PY 2023 £Nil). The outstanding amount owed by Medisave BV Netherlands at 31 December 2024 in respect of goods was £33,703 (PY 2023 £Nil).
 

Medisave (UK) Limited

Detailed Profit and Loss Account for the Year Ended 31 December 2024

Medisave (UK) Limited

Detailed Profit and Loss Account for the Year Ended 31 December 2024

Medisave (UK) Limited

Detailed Profit and Loss Account for the Year Ended 31 December 2024